- Becton Dickinson and Co (NYSE:BDX) issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software.
- Alaris Infusion Central, a standalone software — separate from pumps — provides data from the Alaris pumps, which is not sold in the U.S.
- It allows healthcare providers to monitor infusion data sent from Alaris Plus and Alaris neXus pumps on a computer.
- BD said in the notice that it communicates with customers about cybersecurity vulnerabilities, enabling providers to manage potential risks through awareness and guidance.
- The notice relates to the BD Alaris Infusion Central software, versions 1.1 to 1.3.2.
- BD said the vulnerability received a 7.3 (High) score in the Common Vulnerability Scoring System (CVSS).
- BD said it revised its installation procedure to prevent the vulnerability in future installations. It recommends that users change passwords periodically and ensure physical access controls.
- Price Action: BDX shares are up 0.91% at $244.13 on the last check Friday.
Strongbridge Biopharma Q2 EPS $(0.07) Beats $(0.10) Estimate, Sales $10.00M Beat $8.88M Estimate
Strongbridge Biopharma (NASDAQ:SBBP) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 41.67 percent increase over losses of $(0.12) per share
